Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

ABSTRACT:

Background

The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences in pathological complete response (pCR) rates. Effects on long-term outcome are unknown.

Patients and methods

GENEVIEVE randomized patients with cT2-3, any cN or cT1, cN+/pN_SLN+, centrally confirmed TNBC or luminal B/HER2-negative BC (latter defined as estrogen/progesterone receptor-positive and >14% Ki-67-stained cells) to receive either cabazitaxel 25 mg/m² q3w for four cycles or paclitaxel 80 mg/m² weekly for 12 weeks. Anthracycline-containing chemotherapy was allowed in case of histol

SUBMITTER: Meyer-Wilmes P 

PROVIDER: S-EPMC11061217 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature